Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 14/20 | 0.40 |
| ▸ | PTGER2 | P43116 | 13/20 | 0.40 |
| ▸ | PTGER3 | P43115 | 3/20 | 0.38 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.35 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4096131 | 1.00 | PTGER4 (0.40) | PTGER4PTGER2PTGER3CYP4F2CYP4A11 | |
| SCHEMBL4305387 | 1.00 | PTGER4 (0.40) | PTGER4PTGER2PTGER3CYP4F2CYP4A11 | |
| SCHEMBL4307329 | 0.92 | PTGER4 (0.40) | PTGER4PTGER2PTGER3CYP4F2CYP4A11 | |
| SCHEMBL4078559 | 0.92 | PTGER4 (0.40) | PTGER4PTGER2PTGER3CYP4F2CYP4A11 | |
| SCHEMBL4078562 | 0.92 | PTGER4 (0.40) | PTGER4PTGER2PTGER3CYP4F2CYP4A11 | |
| SCHEMBL4082663 | 0.90 | PTGER4 (0.51) | PTGER4PTGER2PTGER3 | |
| SCHEMBL4082658 | 0.90 | PTGER4 (0.51) | PTGER4PTGER2PTGER3 | |
| SCHEMBL4296516 | 0.90 | PTGER4 (0.51) | PTGER4PTGER2PTGER3 | |
| SCHEMBL4303788 | 0.89 | PTGER4 (0.40) | PTGER4PTGER2PTGER3 | |
| SCHEMBL4094060 | 0.89 | PTGER4 (0.40) | PTGER4PTGER2PTGER3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090270395-A1 | EP4 Receptor Agonist, Compositions and Methods Thereof | MERCK & CO., INC. | 2009-10-29 | — | — | US | claimed |
| EP-1912957-A4 | EP4 RECEPTOR AGONIST, COMPOSITIONS AND METHODS THEREOF | MERCK FROSST CANADA LTD (CA) | 2009-05-13 | — | — | EP | claimed |
| EP-1912957-A1 | EP4 RECEPTOR AGONIST, COMPOSITIONS AND METHODS THEREOF | Merck Frosst Canada Ltd. (CA) | 2008-04-23 | — | — | EP | claimed |
| WO-2007014462-A1 | EP4 RECEPTOR AGONIST, COMPOSITIONS AND METHODS THEREOF | MERCK FROSST CANADA LTD. (CA) | 2007-02-08 | — | — | WO | claimed |
| US-20090270395-A1 | EP4 Receptor Agonist, Compositions and Methods Thereof | MERCK & CO., INC. | 2009-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270395-A1 | EP4 Receptor Agonist, Compositions and Methods Thereof | PTGER4, PTGER1, PTGER3 | PTGER4 1/4885PTGER2 4/4885PTGER3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.